MedTrace Logo

Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2

NCT04626089 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-04-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have metabolic syndrome or type 2 diabetes, which have severe acute respiratory syndrome secondary to SARS-CoV-2.

Conditions

  • Severe Acute Respiratory Syndrome Coronavirus 2
  • Metabolic Syndrome
  • Type 2 Diabetes

Interventions

DRUG

metformin glycinate

Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days

DRUG

Placebo oral tablet

Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Fausto González-Villagrán, MD · Hospital Juárez de México, OPD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04626089 on ClinicalTrials.gov